title: A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.
abstract: This randomized, double-blind, crossover study assessed the efficacy and tolerability of a new rapid onset nasal fentanyl formulation (Fentanyl Pectin Nasal Spray; FPNS) for breakthrough cancer pain (BTCP). Eighty-three of 114 patients experiencing one to four BTCP episodes/day while taking ≥60 mg/day of oral morphine or equivalent successfully identified an effective dose of FPNS during a titration phase and entered a double-blind phase in which 10 BTCP episodes were treated with this effective dose (7) or placebo (3). Compared with placebo, FPNS significantly improved mean summed pain intensity difference (SPID) from 10 min (P<0.05) until 60 min (P<0.0001), including the primary endpoint at 30 min (P<0.0001). FPNS significantly improved pain intensity (PI) scores as early as 5 min (P<0.05); pain intensity difference (PID) from 10 min (P<0.01); and pain relief (PR) scores from 10 min (P<0.001). More patients showed a clinically meaningful (≥ 2-point reduction in PI) pain reduction from 10 min onward (P ≤ 0.01) and 90.6% of the FPNS-treated versus 80.0% of placebo-treated BTCP episodes did not require rescue medication (P<0.001). Approximately 70% of patients were satisfied or very satisfied with the convenience and ease of use of FPNS. Only 5.3% of patients withdrew from treatment due to adverse events, no significant nasal effects were reported, and 87% of patients elected to continue open-label treatment post-study. In this short-term study, FPNS was safe, well tolerated, and rapidly efficacious for BTCP.
authors.affiliation: Beth Israel Medical Center, New York, NY, USA The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA Gabrail Cancer Center, Canton, OH, USA Georgia Center for Cancer Pain Management & Palliative Medicine, Marietta, GA, USA.
authors.forename: Russell K
authors.initials: RK
authors.lastname: Portenoy
authors.forename: Allen W
authors.initials: AW
authors.lastname: Burton
authors.forename: Nashat
authors.initials: N
authors.lastname: Gabrail
authors.forename: Donald
authors.initials: D
authors.lastname: Taylor
mesh_terms: D000281:Administration, Intranasal; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D057194:Intention to Treat Analysis; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D005283:Fentanyl
references.citation: Bennett DS, Burton AW, Fishman S, Fortner BV, McCarberg BH, Miaskowski C, Nash D, Pappagallo M, Payne R, Ray J, Viscusi ER, Wong W. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2. Management. Pharm Ther. 2005;30:354-361.
references.citation: Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, Jackson KA, Lickiss N, Muirden N, Pisasale M, Moulin D, Schulz VN, Rico Pazo MA, Serrano JA, Andersen H, Henriksen HT, Mejholm I, Sjogren P, Heiskanen T, Kalso E, Pere P, Poyhia R, Vuorinen E, Tigerstedt I, Ruismaki P, Bertolino M, Larue F, Ranchere JY, Hege-Scheuing G, Bowdler I, Helbing F, Kostner E, Radbruch L, Kastrinaki K, Shah S, Vijayaram S, Sharma KS, Devi PS, Jain PN, Ramamani PV, Beny A, Brunelli C, Maltoni M, Mercadante S, Plancarte R, Schug S, Engstrand P, Ovalle AF, Wang X, Alves MF, Abrunhosa MR, Sun WZ, Zhang L, Gazizov A, Vaisman M, Rudoy S, Gomez Sancho M, Vila P, Trelis J, Chaudakshetrin P, Koh ML, Van Dongen RT, Vielvoye-Kerkmeer A, Boswell MV, Elliott T, Hargus E, Lutz L. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177-183.
references.citation: Christie JM, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E, Portenoy RK. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998;16:3238-3245.
references.citation: Collins SL, Faura CC, Moor RA, McQuay HJ. Peak plasma concentration after oral morphine: a systematic review. J Pain Symptom Manage. 1998;16:388-402.
references.citation: Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002;46:759-770.
references.citation: Darwish M, Kirby M, Robertson P Jr, Hellriegel E, Jiang JG. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet. 2006;45:843-850.
references.citation: Davies AN, Broadley K, Beighton D. Xerostomia in patients with advanced cancer. J Pain Symptom Manage. 2001;22:820-825.
references.citation: Davies AN, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. J Pain Symptom Manage. 2005;30:496-497.
references.citation: Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage. 2003;25:406-411.
references.citation: Fortner BV, Demarco G, Irving G, Ashley J, Keppler G, Chavez J, Munk J. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003;25:9-18.
references.citation: Gordon SR, Berkey DB, Call RL. Dental need among hospice patients in Colorado: a pilot study. Gerodontics. 1985;1:125-129.
references.citation: Illum L. Nasal drug delivery – possibilities, problems and solutions. J Control Release. 2003;87:187-198.
references.citation: Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 micrograms for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177-1191.
references.citation: Lennernäs B, Hedner T, Holmberg M, Bredenberg S, Nyström C, Lennernäs H. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol. 2005;59:249-253.
references.citation: Lemmens HJ, Wada DR, Munera C, Eltahtawy A, Stanski DR. Enriched analgesic efficacy studies: an assessment by clinical trial simulation. Contemp Clin Trials. 2006;27:165-173.
references.citation: Mercadante S, Radbruch L, Caraceni A, Cherny N, Kaasa S, Nauck F, Ripamonti C, De Conno F. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer. 2002;94:832-839.
references.citation: Moksnes K, Fredheim OM, Klepstad P, Kaasa S, Angelsen A, Nilsen T, Dale O. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference? Eur J Clin Pharmacol. 2008;64:497-502.
references.citation: Ploner M, Lee MC, Wiech K, Bingel U, Tracey I. Prestimulus functional connectivity determines pain perception in humans. Proc Natl Acad Sci USA. 2010;107:355-360.
references.citation: Portenoy R, Bruns D, Shoemaker B, Shoemaker S. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, 1: prevalence and characteristics. J Opioid Manag. 2010;6:97-108.
references.citation: Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-281.
references.citation: Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-134.
references.citation: Portenoy RK, Payne R, Coluzzi P, Raschko JW, Lyss A, Busch MA, Frigerio V, Ingham J, Loseth DB, Nordbrock E, Rhiner M. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain. 1999;79:303-312.
references.citation: Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-811.
references.citation: Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327-334.
references.citation: Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. Br J Clin Pharmacol. 2008;66:266-275.
references.citation: Svendsen KB, Andersen S, Arnason S, Arner S, Breivik H, Heiskanen T, Kalso E, Kongsgaard UE, Sjogren P, Strang P, Bach FW, Jensen TS. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9:195-206.
references.citation: Vasisht N, Gever LN, Tagarro I, Finn AL. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig. 2009;29:647-654.
references.citation: Walker G, Wilcock A, Manderson C, Weller R, Crosby V. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med. 2003;17:219-221.
references.citation: Watson A, El-Deredy W, Iannetti GD, Lloyd D, Tracey I, Vogt BA. Placebo conditioning and placebo analgesia modulate a common brain network during pain anticipation and perception. Pain. 2009;145:24-30.
references.citation: Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv. 2009;6:543-552.